Annexon Biosciences (ANNX) Buy Rating Retained [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
On April 16, Needham analyst Joseph Stringer assigned a Buy rating on Annexon Biosciences and set a price target of $11.00. In March, Annexon president and chief executive officer Douglas Love highlighted progress in the company's portfolio and announced key anticipated milestones. He said: “Grounded in robust vonaprument Phase 2 ARCHER data and strong execution of the ongoing Phase 3 ARCHER II trial, we are on track to report topline pivotal data in the fourth quarter of this year. ARCHER II is the first study to evaluate visual preservation as the primary endpoint in patients with GA (Geographic Atrophy) and the first pivotal study with an aligned global regulatory path.” Love said that the company has also filed for Marketing Authorization Application (MAA) in the EU for tanruprubart and is preparing for potential approval of the first targeted therapy for Guillain-Barré Syndrome (GBS). He added: “We're also focused on the ongoing US/EU FORWARD study which is designed to br
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing [Yahoo! Finance]Yahoo! Finance
- Annexon to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesGlobeNewswire
- Annexon (ANNX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
ANNX
Earnings
- 3/30/26 - Beat
ANNX
Sec Filings
- 4/16/26 - Form PRE
- 4/14/26 - Form 4
- 3/31/26 - Form S-8
- ANNX's page on the SEC website